Floatz logo

Lbl-007

Metastatic Non-small Cell Lung Cancer

BeiGenePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Metastatic Non-small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
Avitinib
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Phase 3BBB
FILGRASTIM
University of California, Irvine
Phase 3BB
Valaciclovir
Candel Therapeutics, Inc.
Phase 3BB
human hyaluronidase isozyme-5 (HYAL5, sperm adhesion molecule 1, SPAM1, hyaluronidase PH-20, EC:3.2.1.35) fragment (3-433, 1-431 in the current sequence) engineered variant with the structural domain replaced by the corresponding region of human hyaluronidase isozyme-1 (HYAL1)(<sup>306</sup>TLSIMRSMKSCLLDDNYMETI<sup>326</sup>><sup>304</sup>SWENTRTKESCQAIKEYMDTT<sup>324</sup>), produced in Chinese hamster ovary (CHO) cells, cell line DG44, glycoform alfa
Merck Sharp & Dohme LLC
Phase 3BB
PEGFILGRASTIM
Merck Sharp & Dohme LLC
Phase 3B

View all 12 →

Same molecule, other indications

Lbl-007 is also rated in:

melanomaDormant
CCC
Indicative ·
51 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →